Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "D3"

54 News Found

Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes
News | August 02, 2022

Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes

The two generic drugs have been launched under the brand names Jankey & Sitenali.


Innate Pharma announces IPH5201 phase 2 study in lung cancer
News | June 04, 2022

Innate Pharma announces IPH5201 phase 2 study in lung cancer

Innate to receive $5M milestone payment from AstraZeneca


LintonPharm to release data on Catumaxomab at ASCO meeting
Biotech | May 30, 2022

LintonPharm to release data on Catumaxomab at ASCO meeting

The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis


New data demonstrate clinical benefit of Roche’s glofitamab
Biotech | May 27, 2022

New data demonstrate clinical benefit of Roche’s glofitamab

Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma


AbbVie showcases its leadership in Rheumatology research with new data across multiple inflammatory joint diseases
Biotech | May 24, 2022

AbbVie showcases its leadership in Rheumatology research with new data across multiple inflammatory joint diseases

The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually


Micro-Tech Endoscopy partners with Wision A.I. to distribute polyp detection software in the U.S.
Medical Device | May 23, 2022

Micro-Tech Endoscopy partners with Wision A.I. to distribute polyp detection software in the U.S.

The technology was able to identify approximately 32 percent more adenomas than standard colonoscopy procedures


Antengene announces commercial availability of Xpovio in China
Biotech | May 16, 2022

Antengene announces commercial availability of Xpovio in China

The drug will be available in 600 hospitals and 105 DTPs


Sarclisa (isatuximab) combination provides unprecedented median progression-free survival
Biotech | May 15, 2022

Sarclisa (isatuximab) combination provides unprecedented median progression-free survival

The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone


Sanofi announces €300 million collaboration with Blackstone Life Sciences
Biotech | March 16, 2022

Sanofi announces €300 million collaboration with Blackstone Life Sciences

The investment will accelerate the overall Sarclisa development program


Bristol Myers Squibb receives approval for Abecma in Japan
Drug Approval | January 21, 2022

Bristol Myers Squibb receives approval for Abecma in Japan

It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan